ANIK Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

28.88M

-5.64%

0.020

-166.67%

28.11M

+7.42%

0.000

-100%

29.50M

+4.54%

0.070

-153.85%

Estimates Revision

The market is revising Downward the revenue expectations for Anika Therapeutics, Inc. (ANIK) for FY2025, with the revenue forecasts being adjusted by -0.19% over the past three months. During the same period, the stock price has changed by -0.32%.

Revenue Estimates for FY2025

Revise Downward

-0.19%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-0.32%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast ANIK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANIK is 16.00 USD with a low forecast of 16.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

16.00

Averages

16.00

High

16.00

Current: 0.000

Low

16.00

Averages

16.00

High

16.00

Barrington

Michael Petusky

Outperform

maintain

$15 -> $16

2025-11-06

Reason

Barrington

Michael Petusky

Price Target

$15 -> $16

2025-11-06

maintain

Outperform

Reason

Barrington analyst Michael Petusky raised the firm's price target on Anika Therapeutics to $16 from $15 and keeps an Outperform rating on the shares. The firm, which continues to think shares are "meaningfully undervalued," says "it appears that the company agrees" based on its recent decision to commence a $15M 10b5-1 share repurchase that it expects to complete by this June.

Barrington

Outperform

maintain

$20 -> $19

2025-05-12

Reason

Barrington

Price Target

$20 -> $19

2025-05-12

maintain

Outperform

Reason

Barrington lowered the firm's price target on Anika Therapeutics to $19 from $20 and keeps an Outperform rating on the shares. While the Q1 miss is "frustrating," Anika's product pipeline holds material value that will "begin to be unlocked in a significant way" over the next two years, the analyst tells investors in a research note. The firm thinks the recent share price weakness "provides a very good entry point for new investors and is a great opportunity to add to positions for long-suffering, current investors."

Barrington Research

Michael Petusky

Buy

Maintains

$25 → $20

2025-03-13

Reason

Barrington Research

Michael Petusky

Price Target

$25 → $20

2025-03-13

Maintains

Buy

Reason

Barrington lowered the firm's price target on Anika Therapeutics to $20 from $25 and keeps an Outperform rating on the shares. Anika management reduced its previous adjusted EBITDA guidance for FY25, which had previously been forecast to be a double-digit margin but is now expected to be 8-10%, with pricing weakness in osteoarthritis pain management in the U.S. appearing to be the primary reason for the lowered outlook, the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for Anika Therapeutics Inc (ANIK.O) is 51.94, compared to its 5-year average forward P/E of 197.73. For a more detailed relative valuation and DCF analysis to assess Anika Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

197.73

Current PE

51.94

Overvalued PE

851.46

Undervalued PE

-456.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-50.17

Current EV/EBITDA

15.72

Overvalued EV/EBITDA

347.45

Undervalued EV/EBITDA

-447.79

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.41

Current PS

1.17

Overvalued PS

3.24

Undervalued PS

1.59

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ANIK News & Events

Events Timeline

No data

News

7.0

2025-12-30Businesswire

Anika Therapeutics Shares Plunge 27.42% After Clinical Trial Results Fail to Meet Primary Endpoints

7.0

2025-12-30Newsfilter

Anika Therapeutics Faces Investigation After 27.42% Stock Drop Following Clinical Trial Results

7.0

2025-12-06Globenewswire

Anika Therapeutics Faces Investigation After Hyalofast Trial Misses Key Endpoints

People Also Watch

Frequently Asked Questions

What is Anika Therapeutics Inc (ANIK) stock price today?

The current price of ANIK is 9.39 USD — it has decreased -1.68 % in the last trading day.

What is Anika Therapeutics Inc (ANIK)'s business?

Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.

What is the price predicton of ANIK Stock?

What is Anika Therapeutics Inc (ANIK)'s revenue for the last quarter?

Anika Therapeutics Inc revenue for the last quarter amounts to 27.82M USD, decreased -28.22 % YoY.

What is Anika Therapeutics Inc (ANIK)'s earnings per share (EPS) for the last quarter?

Anika Therapeutics Inc. EPS for the last quarter amounts to -0.16 USD, decreased -92.12 % YoY.

What changes have occurred in the market's expectations for Anika Therapeutics Inc (ANIK)'s fundamentals?

How many employees does Anika Therapeutics Inc (ANIK). have?

Anika Therapeutics Inc (ANIK) has 288 emplpoyees as of January 09 2026.

What is Anika Therapeutics Inc (ANIK) market cap?

Today ANIK has the market capitalization of 137.72M USD.